ArticleNeurology2019
Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04524039 (Intermittent Theta Burst Stimulation), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Depression in Patients With Multiple Sclerosis: a Randomized Controlled Study
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Measures of Comorbidities and Frailty in Multiple Sclerosis-Systematic Review on Evidence and Applicability of Utilized Scoring Systems in Clinical Routine and Real-World Data.European journal of neurology · 2025Pooled it
- Best practice exercise for emerging depression in multiple sclerosis: A systematic review and meta-analysis.Clinical rehabilitation · 2024Pooled it
- Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial.The Lancet. Digital health · 2023Trial
- Impact of mindfulness training on emotion regulation in multiple sclerosis: Secondary analysis of a pilot randomized controlled trial.Rehabilitation psychology · 2022Trial
- Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.Neurology · 2020Trial
- Shedding Light on Interaction Between Neurological Symptoms and Psychiatric Episodes in Multiple Sclerosis: Novel Hypothesis and Therapeutic Avenues.Molecular neurobiology · 2026Review
- Depression as a Disease of White Matter Network Disruption: Learning From Multiple Sclerosis.Biological psychiatry · 2026Review
- Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion.European journal of neurology · 2026Article
- Investigating Depression and MRI Associations in Middle Eastern Relapsing-Remitting Multiple Sclerosis.Journal of biomedical physics & engineering · 2026Article
- Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.Journal of neurology · 2026Article
- Optimizing Identification and Management of Depression in Neurological Diseases: A Narrative Review and Expert Perspective.Neuropsychiatric disease and treatment · 2026Article
- Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.Annals of neurology · 2025Article
- Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage.European journal of neurology · 2025Observational
- Sex-Related Differences in Lifestyle Factors Affecting Multiple Sclerosis Susceptibility and Disease Progression.Brain sciences · 2025Review
- Understanding Depression in People Living with Multiple Sclerosis: A Narrative Review of Recent Literature.Neurology and therapy · 2025Review
- Investigating depression in multiple sclerosis: an Italian Delphi consensus on clinical manifestations, diagnosis and treatment.Frontiers in psychiatry · 2025Article
- Evidence of symptom specificity for depression in multiple sclerosis: A two sample Mendelian randomization study.Multiple sclerosis and related disorders · 2024Article
- Comorbidity and Disease Activity in Multiple Sclerosis.JAMA neurology · 2024Article
- Trends in central nervous system-active polypharmacy among people with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.Journal of neurology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDepression is common in multiple sclerosis (MS), but its impact on disability worsening has not yet been determined. We explored the risk of disability worsening associated with depression in a nationwide longitudinal cohort.
methodsThis retrospective cohort study used linked data from 3 Swedish nationwide registries: the MS Register, National Patient Register, and Prescribed Drug Register. Two incident cohorts were developed: cohort 1 included all registered cases of MS in the MS Registry (2001-2014) with depression defined as ≥1 ICD-10 code for depression; and cohort 2 comprised all cases of MS in the MS Registry (2005-2014) with depression defined as ≥1 prescription filled for an antidepressant. Cox regression models were used to compare the risk of reaching sustained disability milestone scores of 3.0, 4.0, and 6.0 on the Expanded Disability Status Scale (EDSS) between persons with MS with and without depression.
resultsCohort 1 included 5,875 cases; 502 (8.5%) had depression. Cohort 2 had 3,817 cases; 1,289 (33.8%) were prescribed an antidepressant. Persons with depression were at a significantly higher risk of reaching sustained EDSS scores of 3.0, 4.0, and 6.0, with hazard ratios of 1.50 (95% confidence interval [CI] 1.20-1.87), 1.79 (95% CI 1.40-2.29), and 1.89 (95% CI 1.38-2.57), respectively. A similar increased risk among persons exposed to antidepressants was observed, with hazard ratios of 1.37 (95% CI 1.18-1.60), 1.93 (95% CI 1.61-2.31), and 1.86 (95% CI 1.45-2.40) for sustained EDSS scores of 3.0, 4.0, and 6.0, respectively.
conclusionPersons with MS and comorbid depression had a significantly increased risk of disability worsening. This finding highlights the need for early recognition and appropriate treatment of depression in persons with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.